The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. We identified a chiral VPA derivative, (S)-2-pentyl-4-pentynoic acid, previously characterized as HDAC inhibitor that induced massive programmed cell death in a strongly enantioselective manner in U937 histiocytic lymphoma cells and NB4 acute promyelocytic leukemia cells. By performing fluorescence-activated cell sorting and Western blotting analyses, we established that enantiomer (S)-2-pentyl-4-pentynoic acid has higher apoptosis-inducing potential than VPA itself. The optic antipode (R)-2-pentyl-4-pentynoic acid and VPA caused under the same conditions only a weak growth inhibition without inducing cell differentiation and apoptosis. (S)-2-pentyl-4-pentynoic acid is more apoptogenic than VPA and displays enantioselective anti-cancer properties that warrant further research regarding the mechanistic basis of its activity and its potential use in cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00204-012-0930-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells.
Arch Toxicol
February 2013
Institute of Genetics and Molecular Biology of the Cell, 1 rue Laurent Fries, BP 10142, 67404 Illkirch Cedex, Strasbourg, France.
The aim of this study was to identify valproic acid (VPA) analogs with a broad spectrum of anti-cancer activities and an increased apoptosis-inducing potential compared with the parent VPA, which is enrolled as histone deacetylase (HDAC) inhibitor in a large number of clinical trials. We identified a chiral VPA derivative, (S)-2-pentyl-4-pentynoic acid, previously characterized as HDAC inhibitor that induced massive programmed cell death in a strongly enantioselective manner in U937 histiocytic lymphoma cells and NB4 acute promyelocytic leukemia cells. By performing fluorescence-activated cell sorting and Western blotting analyses, we established that enantiomer (S)-2-pentyl-4-pentynoic acid has higher apoptosis-inducing potential than VPA itself.
View Article and Find Full Text PDFShort-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells.
Toxicol Sci
June 2011
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala SE-751 24, Sweden.
Prediction of developmental toxicity in vitro could be based on short-time toxicogenomic endpoints in embryo-derived cell lines. Microarray studies in P19 mouse embryocarcinoma cells and mouse embryos have indicated that valproic acid (VPA), an inducer of neural tube defects, deregulates the expression of many genes, including those critically involved in neural tube development. In this study, we exposed undifferentiated R1 mouse embryonic stem cells to VPA and VPA analogs for 6 h and used CodeLink whole-genome expression microarrays to define VPA-responsive genes correlating with teratogenicity.
View Article and Find Full Text PDFPotent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction.
Neurosci Lett
June 2010
Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bldg. 10, Rm. 3D-38, 10 Center Dr, Bethesda, MD 20892-1363, USA.
Emerging evidence suggests that the neuroprotective effects of valproic acid (VPA) occur via inhibition of histone deacetylases (HDACs) and activation of gene expression. This study assessed the ability of four VPA derivatives to cause histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons. We found that (S)-2-pentyl-4-pentynoic acid (compound III) and (+/-)-2-hexyl-4-pentynoic acid (compound V) were far more potent and robust than VPA in inducing histone hyperacetylation and protecting against glutamate excitotoxicity.
View Article and Find Full Text PDFS-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
Drug Metab Dispos
April 2006
University of Veterinary Medicine Hannover-Foundation, Center for Systemic Neuroscience Hannover, Center for Food Science, Department of Food Toxicology and Chemical Analysis-Food Toxicology, Bischofsholer Damm 15, 30173 Hannover, Germany.
Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function. Whereas the classical HDAC inhibitor trichostatin A is active only as a hydroxamate but not as a carboxylic acid, we found that neither VPA amides nor hydroxamates inhibit HDACs, but can cause NTDs; e.g.
View Article and Find Full Text PDFIncreased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition.
Invest Ophthalmol Vis Sci
September 2005
Institut für Medizinische Virologie, Klinikum der J. W. Goethe-Universität, Paul-Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany.
Article Synopsis
- The study investigates how valproic acid (VPA) affects human cytomegalovirus (HCMV) replication in retinal pigment epithelial (RPE) cells, revealing that VPA concentrations less than or equal to 1 mM can increase HCMV antigen expression and replication significantly.
- Results show that VPA enhances HCMV replication through the inhibition of histone deacetylase (HDAC) and also activates Erk 1/2 phosphorylation without depending on it.
- The findings suggest that patients at risk for HCMV retinitis receiving VPA or other HDAC inhibitors need close monitoring due to the potential risk of increased virus replication.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!